TABLE 3 Change from CHEST-1 baseline in NT-proBNP, Borg dyspnoea score, EQ-5D score and LPH score during CHEST-1 and CHEST-2
Former riociguatFormer placeboTotal population
CHEST-1 week 16CHEST-2 week 12CHEST-2 1 yearCHEST-1 week 16CHEST-2 week 12CHEST-2 1 yearCHEST-2 1 year
NT-proBNP pg·mL−1−475±1428 (134)−316±2350 (130)−375±1182 (102)+146±709 (68)−508±1137 (65)−505±1591 (47)−416±1321 (149)
Borg dyspnoea score#−1.05±2.26 (154)−1.00±2.36 (145)−0.80±2.41 (113)−0.06±2.15 (81)−0.70±1.93 (75)−0.57±1.98 (58)−0.72±2.27 (171)
EQ-5D score+0.10±0.23 (152)+0.13±0.24 (146)+0.12±0.29 (113)−0.03±0.26 (79)+0.07±0.23 (75)+0.01±0.30 (58)+0.08±0.30 (171)
LPH score+−9.3±16.3 (152)−13.2±16.7 (138)§−5.0±15.0 (79)−10.8±18.9 (67)§
  • Data are presented as mean±sd (n). NT-proBNP: N-terminal prohormone of brain natriuretic peptide; EQ-5D: EuroQol 5 Dimensions; LPH: Living with Pulmonary Hypertension. #: the Borg dyspnoea scale ranges from 0 to 10, with 0 representing no dyspnoea and 10 maximal dyspnoea; : Scores on the EQ-5D self-report questionnaire range from −0.6 to 1.0, with higher scores indicating a better quality of life; +: Scores on the LPH questionnaire (an adaptation of the Minnesota Living with Heart Failure Questionnaire) range from 0 to 105, with higher scores indicating worse quality of life; §: CHEST-2 week 8 data are shown for LPH score.